The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study
作者： Daniel M. Green , Vikki G. Nolan , Pamela J. Goodman , John A. Whitton , DeoKumar Srivastava
DOI: 10.1002/PBC.24679
关键词:
摘要: BACKGROUND Estimation of the risk adverse long-term outcomes such as second malignant neoplasms and infertility often requires reproducible quantification exposures. The method for should be easily utilized valid across different study populations. widely used Alkylating Agent Dose (AAD) score is derived from drug dose distribution population thus cannot comparisons populations each will have a unique doses.
utsystem.edu参考文章(49)
Bakemeier Rf, Bennett Jm, Glick Jh, Prosnitz Lr, Orlow El, Barnes Jm, Costello W, Neiman Rs, Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group. Cancer treatment reports. ,vol. 66, pp. 855- ,(1982)
A. Aviles, E. L. Garcia, D. Lopez-Vancell, V. Torras, J. C. Diaz-Maqueo, Randomized study for the treatment of advanced Hodgkin's disease: MOPP vs. LOPP. Archivos de investigación médica. ,vol. 22, pp. 45- 50 ,(1991)
B.W. Hancock, Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation. Radiotherapy and Oncology. ,vol. 7, pp. 215- 221 ,(1986) , 10.1016/S0167-8140(86)80032-9
D L Longo, V T DeVita, P L Duffey, M N Wesley, D C Ihde, S M Hubbard, M Gilliom, E S Jaffe, J Cossman, R I Fisher, Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal of Clinical Oncology. ,vol. 9, pp. 25- 38 ,(1991) , 10.1200/JCO.1991.9.1.25
William M. Crist, James R. Anderson, Jane L. Meza, Christopher Fryer, R. Beverly Raney, Frederick B. Ruymann, John Breneman, Stephen J. Qualman, Eugene Wiener, Moody Wharam, Thom Lobe, Bruce Webber, Harold M. Maurer, Sarah S. Donaldson, Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease Journal of Clinical Oncology. ,vol. 19, pp. 3091- 3102 ,(2001) , 10.1200/JCO.2001.19.12.3091
Claudia Ceccarelli, Walter Bencivelli, Donata Morciano, Aldo Pinchera, Furio Pacini, 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. The Journal of Clinical Endocrinology and Metabolism. ,vol. 86, pp. 3512- 3515 ,(2001) , 10.1210/JCEM.86.8.7719
W. M. Nicholson, M. E. J. Beard, D. Crowther, A. G. Stansfeld, C. P. Vartan, J. S. Malpas, G. H. Fairley, R. B. Scott, Combination Chemotherapy in Generalized Hodgkin's Disease BMJ. ,vol. 3, pp. 7- 10 ,(1970) , 10.1136/BMJ.3.5713.7
Daniel M. Green, Toana Kawashima, Marilyn Stovall, Wendy Leisenring, Charles A. Sklar, Ann C. Mertens, Sarah S. Donaldson, Julianne Byrne, Leslie L. Robison, Fertility of Male Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Journal of Clinical Oncology. ,vol. 28, pp. 332- 339 ,(2010) , 10.1200/JCO.2009.24.9037
David T. Kaung, Henry P. Close, Richard M. Whittington, Mary Ellen Patno, Comparison of busulfan and cyclophosphamide in the treatment of chronic myelocytic leukemia Cancer. ,vol. 27, pp. 608- 612 ,(1971) , 10.1002/1097-0142(197103)27:3<608::AID-CNCR2820270315>3.0.CO;2-L
S B Kaye, C A Juttner, I E Smith, A Barrett, D E Austin, M J Peckham, T J McElwain, Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. British Journal of Cancer. ,vol. 39, pp. 168- 174 ,(1979) , 10.1038/BJC.1979.27